(I love how this company patents stuff based on someone else's
research - now THAT's capitalism!)
SOURCE: Medistem Laboratories
Jan 21, 2008 08:05 ET
Medistem Files Patent Application on Therapeutic Cell Population
Found in Fat Tissue
Recent Findings Indicate Novel Means of Controlling Autoimmunity and
Transplant Rejection
T-Reg Populations as found in the spleen, bone marrow, and fat
SCOTTSDALE, AZ--(Marketwire - January 21, 2008) - Medistem
Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) has filed a patent
application covering recent findings documenting the existence of
high concentrations of therapeutic anti-inflammatory cells, called T
regulatory cells, in fat tissue. The findings, confirmed by Medistem
collaborator Dr. Hao Wang at the Lawson Health Research Institute,
London, Canada, supports the possibility that the therapeutic effects
previously observed by other groups using fat stem cells may be not
be strictly due to the stem cells in the fat tissue but to the T
regulatory cell population.
"The patent application covers not only methods of using fat tissue
for suppressing inflammatory and autoimmunity, but also methods of
expanding and increasing activity of these therapeutic cells," said
Neil Riordan PhD, President and CEO of Medistem. He continued, "The
current findings support development of therapeutics that suppress
diseases with the body's own natural means, avoiding the need for
toxic non-specific immune suppressants and steroids. If treatments
can be developed based on these findings, patients could rely on T
regulatory cells found in their own fat tissue, instead of non-
specific drugs."
Medistem is currently working with several academic collaborators to
develop regenerative and immune modulatory therapeutics using
cellular populations derived from the fat tissue, cord blood, and as
recently published, menstrual blood.
"Autoimmune diseases affect approximately 5-8 percent of the American
population, being the 3rd major cause of illness behind cancer and
heart disease. We are confident that our findings and intellectual
property positioning in this area may enable Medistem to start
addressing a substantially relevant unmet need," concluded Chris
McGuinn, COO of Medistem.
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers,
develops, and commercializes adult stem cell products that address
serious medical conditions. While drug discovery and development is
its primary focus, Medistem has compiled a body of proprietary
technologies it outlicenses to commercial entities in markets where
stem cell administration is permissible. Due to its licensee
relationships and collaborative efforts with respected institutions,
Medistem believes it is well positioned to be a leading developer of
adult stem cell products.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation
of an offer to buy any of our securities. This document contains
certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements may include projections of matters that affect revenue,
the ability to develop or license certain technologies and receive
associated licensing fees; operating expenses or net earnings;
projections of capital expenditures; projections of growth; hiring
plans; plans for future operations; financing needs or plans; plans
relating to the company's products and services; and assumptions
relating to the foregoing.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
information.
Some of the important factors that could cause the company's actual
results to differ materially from those projected in forward-looking
statements made by the company include, but are not limited to, the
following: the company's ability to anticipate future license fees,
technology development limitations, intense competition, risk of
business interruption, management of rapid growth, need for
additional financing, regulatory approvals and requirements,
dependence on key personnel and research, management and other
administrative costs.
These factors are discussed in greater detail in the company's
quarterly and annual periodic reports, all as filed with the
Securities and Exchange Commission.
Medistem Laboratories, Inc.
Chris McGuinn
602-318-3535
http://www.medistem
http://www.marketwi
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment